A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
787actual
Sites
49
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-15 | actual | When the study began enrolling |
| Primary completion | 2025-08-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-10 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Rimegepant — also filed as PF-07899801, BHV-3000
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMean change from the Observation Phase (OP) in the number of migraine days per month over the entire Double Blind Treatment (DBT) Phase
measured OP (up to 4 weeks) and Weeks 1-12 of the DBT phase
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed